Trial results

$ACAD — remlifanserin

ACADIA PHARMACEUTICALS INC (ACAD) remlifanserin: trial results in Lewy Body Dementia Psychosis (LBDP), 2027.

Research by Catalyst Intel

The catalyst

"We initiated an additional Phase 2 study of remlifanserin in LBDP in September 2025 and expect a data readout in the fourth quarter 2027."

— Acadia Pharmaceuticals Inc., 10-Q filed 2026-11-05 · the filing. Checked word for word against the stored document when this page was built; a sentence that did not check out would not be here.

Event id

ACAD-REMLIFANSERI-2026

Company

ACADIA PHARMACEUTICALS INC

Kind

Trial results

Indication

Lewy Body Dementia Psychosis (LBDP)

Window

2027-01-01 – 2027-12-31

Status

slate

The bar

No bar has been published for this event yet.

Verdicts

Sealed with the bar. Any verdict for this event reaches this page on 2028-01-30; subscribers get it on the day.